Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Exercise Test | 78 | 2025 | 2180 | 8.210 |
Why?
|
Exercise Tolerance | 59 | 2024 | 841 | 7.960 |
Why?
|
Heart Failure | 109 | 2024 | 11840 | 7.110 |
Why?
|
Oxygen Consumption | 38 | 2025 | 1870 | 4.790 |
Why?
|
Stroke Volume | 71 | 2024 | 5596 | 4.730 |
Why?
|
Hypertension, Pulmonary | 20 | 2024 | 1604 | 3.360 |
Why?
|
Exercise | 38 | 2024 | 5937 | 2.910 |
Why?
|
Hemodynamics | 22 | 2024 | 4184 | 2.670 |
Why?
|
Anemia, Iron-Deficiency | 7 | 2023 | 374 | 2.380 |
Why?
|
Ventricular Function, Left | 30 | 2024 | 3928 | 2.260 |
Why?
|
Ventricular Dysfunction, Left | 11 | 2022 | 2136 | 1.860 |
Why?
|
Pulmonary Wedge Pressure | 11 | 2024 | 276 | 1.800 |
Why?
|
Hematinics | 4 | 2023 | 282 | 1.620 |
Why?
|
Heart Failure, Systolic | 4 | 2015 | 135 | 1.600 |
Why?
|
Dyspnea | 9 | 2024 | 1352 | 1.580 |
Why?
|
Heart Rate | 18 | 2024 | 4204 | 1.520 |
Why?
|
Vascular Resistance | 10 | 2022 | 941 | 1.360 |
Why?
|
Cardiomyopathy, Hypertrophic | 9 | 2024 | 1339 | 1.300 |
Why?
|
Heart-Assist Devices | 10 | 2022 | 1296 | 1.240 |
Why?
|
Iron Compounds | 3 | 2019 | 28 | 1.240 |
Why?
|
Ventricular Function, Right | 6 | 2018 | 629 | 1.230 |
Why?
|
Cardiac Output | 9 | 2024 | 840 | 1.190 |
Why?
|
Pulmonary Ventilation | 5 | 2023 | 377 | 1.120 |
Why?
|
Ventricular Dysfunction, Right | 5 | 2016 | 645 | 1.090 |
Why?
|
Heart Transplantation | 15 | 2024 | 3310 | 1.000 |
Why?
|
Phosphodiesterase Inhibitors | 5 | 2012 | 213 | 0.990 |
Why?
|
Phosphodiesterase 5 Inhibitors | 10 | 2019 | 103 | 0.980 |
Why?
|
Sulfones | 10 | 2014 | 447 | 0.980 |
Why?
|
Metabolome | 7 | 2020 | 1005 | 0.970 |
Why?
|
Oxygen | 9 | 2023 | 4241 | 0.970 |
Why?
|
Purines | 12 | 2016 | 615 | 0.900 |
Why?
|
Pulmonary Circulation | 5 | 2016 | 741 | 0.880 |
Why?
|
Piperazines | 12 | 2015 | 2549 | 0.870 |
Why?
|
Ferric Compounds | 5 | 2024 | 368 | 0.870 |
Why?
|
Pulmonary Gas Exchange | 8 | 2020 | 389 | 0.850 |
Why?
|
Pulmonary Artery | 6 | 2022 | 1935 | 0.810 |
Why?
|
Rest | 4 | 2024 | 942 | 0.800 |
Why?
|
Humans | 217 | 2025 | 765968 | 0.740 |
Why?
|
Middle Aged | 119 | 2025 | 223009 | 0.730 |
Why?
|
Respiratory Protective Devices | 1 | 2020 | 47 | 0.700 |
Why?
|
Male | 146 | 2025 | 363698 | 0.670 |
Why?
|
Urea | 1 | 2022 | 448 | 0.670 |
Why?
|
Aged | 89 | 2025 | 171117 | 0.660 |
Why?
|
Cardiovascular Agents | 2 | 2024 | 851 | 0.660 |
Why?
|
Double-Blind Method | 27 | 2024 | 12437 | 0.640 |
Why?
|
Ferritins | 4 | 2021 | 600 | 0.620 |
Why?
|
Heart Ventricles | 8 | 2020 | 3832 | 0.610 |
Why?
|
Cardiovascular Diseases | 16 | 2025 | 15652 | 0.600 |
Why?
|
Blood Pressure | 16 | 2024 | 8532 | 0.590 |
Why?
|
Female | 136 | 2025 | 396112 | 0.580 |
Why?
|
Health Status | 8 | 2024 | 4080 | 0.580 |
Why?
|
Ventricular Remodeling | 9 | 2018 | 1272 | 0.560 |
Why?
|
Metabolomics | 4 | 2025 | 1668 | 0.530 |
Why?
|
Cheyne-Stokes Respiration | 2 | 2014 | 38 | 0.530 |
Why?
|
Cardiac Resynchronization Therapy | 4 | 2016 | 562 | 0.520 |
Why?
|
Tricarboxylic Acids | 1 | 2016 | 26 | 0.520 |
Why?
|
Hypertrophy, Left Ventricular | 6 | 2017 | 855 | 0.510 |
Why?
|
Natriuretic Peptide, Brain | 12 | 2024 | 1736 | 0.510 |
Why?
|
3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2006 | 56 | 0.500 |
Why?
|
Heart | 6 | 2022 | 4414 | 0.490 |
Why?
|
Tissue Donors | 5 | 2024 | 2395 | 0.480 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2016 | 120 | 0.480 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2014 | 109 | 0.440 |
Why?
|
Physical Endurance | 5 | 2017 | 368 | 0.420 |
Why?
|
Obesity | 15 | 2024 | 13076 | 0.420 |
Why?
|
Mitral Valve | 1 | 2021 | 1476 | 0.410 |
Why?
|
Maltose | 2 | 2024 | 39 | 0.410 |
Why?
|
Physical Fitness | 5 | 2022 | 742 | 0.390 |
Why?
|
Echocardiography | 12 | 2024 | 5045 | 0.390 |
Why?
|
Diabetic Cardiomyopathies | 2 | 2024 | 85 | 0.390 |
Why?
|
Adult | 64 | 2025 | 223044 | 0.390 |
Why?
|
Mitral Valve Insufficiency | 2 | 2021 | 1414 | 0.390 |
Why?
|
Vasodilator Agents | 6 | 2016 | 988 | 0.390 |
Why?
|
Arginine | 1 | 2016 | 933 | 0.390 |
Why?
|
Peptide Fragments | 12 | 2024 | 5125 | 0.390 |
Why?
|
Prognosis | 16 | 2024 | 29922 | 0.390 |
Why?
|
Physical Exertion | 3 | 2023 | 665 | 0.380 |
Why?
|
Myocardial Contraction | 6 | 2024 | 1515 | 0.380 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2015 | 345 | 0.370 |
Why?
|
Aldosterone | 2 | 2015 | 881 | 0.370 |
Why?
|
Angiotensin Receptor Antagonists | 4 | 2023 | 1061 | 0.370 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1032 | 0.370 |
Why?
|
Body Mass Index | 7 | 2024 | 13039 | 0.350 |
Why?
|
Metabolic Networks and Pathways | 3 | 2012 | 798 | 0.350 |
Why?
|
Lung | 4 | 2022 | 10033 | 0.350 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2014 | 363 | 0.350 |
Why?
|
Time Factors | 25 | 2024 | 40065 | 0.340 |
Why?
|
Quality of Life | 14 | 2024 | 13462 | 0.340 |
Why?
|
Respiration | 3 | 2022 | 1653 | 0.340 |
Why?
|
Nitric Oxide | 3 | 2016 | 2143 | 0.330 |
Why?
|
Polysaccharides | 1 | 2016 | 1016 | 0.320 |
Why?
|
Treatment Outcome | 33 | 2024 | 65188 | 0.320 |
Why?
|
Myocardium | 5 | 2020 | 4760 | 0.310 |
Why?
|
Systole | 4 | 2020 | 935 | 0.310 |
Why?
|
Muscle Tonus | 1 | 2008 | 82 | 0.310 |
Why?
|
Athletes | 5 | 2023 | 1162 | 0.300 |
Why?
|
Administration, Oral | 7 | 2024 | 4015 | 0.290 |
Why?
|
Iron | 4 | 2023 | 1816 | 0.290 |
Why?
|
Blood | 1 | 2010 | 597 | 0.280 |
Why?
|
Heart Diseases | 3 | 2020 | 2821 | 0.280 |
Why?
|
Respiratory Mechanics | 1 | 2011 | 717 | 0.280 |
Why?
|
Aldehyde Reductase | 2 | 2024 | 67 | 0.280 |
Why?
|
Transferrin | 3 | 2019 | 283 | 0.280 |
Why?
|
Phenotype | 9 | 2023 | 16721 | 0.280 |
Why?
|
Helicobacter | 1 | 2007 | 111 | 0.270 |
Why?
|
Antiviral Agents | 1 | 2019 | 3050 | 0.270 |
Why?
|
Heart Injuries | 1 | 2008 | 206 | 0.270 |
Why?
|
Prospective Studies | 28 | 2022 | 54802 | 0.260 |
Why?
|
Lung Diseases, Interstitial | 1 | 2015 | 939 | 0.260 |
Why?
|
Muscle, Skeletal | 5 | 2017 | 4958 | 0.260 |
Why?
|
Predictive Value of Tests | 10 | 2021 | 15398 | 0.260 |
Why?
|
Biomedical Technology | 1 | 2008 | 210 | 0.250 |
Why?
|
Benzhydryl Compounds | 2 | 2023 | 939 | 0.250 |
Why?
|
Pericarditis | 1 | 2007 | 137 | 0.250 |
Why?
|
Pulmonary Veins | 1 | 2011 | 757 | 0.240 |
Why?
|
Respiratory Function Tests | 3 | 2021 | 1693 | 0.240 |
Why?
|
Glomerular Filtration Rate | 3 | 2024 | 2233 | 0.240 |
Why?
|
Tissue and Organ Procurement | 3 | 2024 | 989 | 0.240 |
Why?
|
Follow-Up Studies | 17 | 2024 | 39193 | 0.230 |
Why?
|
Insulin Resistance | 7 | 2023 | 3985 | 0.230 |
Why?
|
Retrospective Studies | 22 | 2024 | 81514 | 0.230 |
Why?
|
Sequoia | 1 | 2023 | 6 | 0.230 |
Why?
|
Energy Metabolism | 2 | 2017 | 2892 | 0.220 |
Why?
|
Waiting Lists | 2 | 2019 | 777 | 0.220 |
Why?
|
Cardiovascular System | 2 | 2022 | 841 | 0.220 |
Why?
|
Cohort Studies | 16 | 2024 | 41649 | 0.210 |
Why?
|
Models, Cardiovascular | 3 | 2016 | 978 | 0.210 |
Why?
|
Helicobacter Infections | 1 | 2007 | 390 | 0.210 |
Why?
|
Benzylamines | 4 | 2024 | 251 | 0.210 |
Why?
|
Lung Diseases | 1 | 2013 | 1940 | 0.210 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8041 | 0.210 |
Why?
|
Anaerobic Threshold | 2 | 2015 | 51 | 0.210 |
Why?
|
Coronary Thrombosis | 1 | 2006 | 440 | 0.210 |
Why?
|
Allopurinol | 1 | 2024 | 203 | 0.210 |
Why?
|
Uracil | 4 | 2024 | 210 | 0.210 |
Why?
|
Sulfonamides | 3 | 2019 | 1984 | 0.200 |
Why?
|
Vascular Patency | 1 | 2006 | 912 | 0.200 |
Why?
|
Risk Assessment | 9 | 2024 | 24282 | 0.200 |
Why?
|
Dietary Supplements | 3 | 2023 | 3425 | 0.200 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2008 | 1499 | 0.200 |
Why?
|
Proportional Hazards Models | 4 | 2024 | 12509 | 0.200 |
Why?
|
Environmental Microbiology | 1 | 2002 | 47 | 0.190 |
Why?
|
Organ Transplantation | 2 | 2022 | 1174 | 0.190 |
Why?
|
Ventriculography, First-Pass | 2 | 2013 | 20 | 0.190 |
Why?
|
Myocardial Ischemia | 6 | 2014 | 2128 | 0.190 |
Why?
|
Feasibility Studies | 3 | 2021 | 5302 | 0.190 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2004 | 477 | 0.190 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2021 | 89 | 0.180 |
Why?
|
Enterovirus | 1 | 2002 | 69 | 0.180 |
Why?
|
Heart Failure, Diastolic | 1 | 2021 | 77 | 0.180 |
Why?
|
Autonomic Denervation | 1 | 2020 | 4 | 0.180 |
Why?
|
Myocytes, Cardiac | 3 | 2016 | 1668 | 0.170 |
Why?
|
Running | 2 | 2015 | 488 | 0.170 |
Why?
|
Proteomics | 3 | 2024 | 3910 | 0.170 |
Why?
|
MicroRNAs | 5 | 2018 | 3785 | 0.170 |
Why?
|
Pulmonary Embolism | 2 | 2023 | 2598 | 0.170 |
Why?
|
Pyrazoles | 2 | 2020 | 2033 | 0.160 |
Why?
|
Multicenter Studies as Topic | 2 | 2022 | 1731 | 0.160 |
Why?
|
Biphenyl Compounds | 2 | 2022 | 1019 | 0.160 |
Why?
|
Drug Combinations | 3 | 2022 | 2077 | 0.160 |
Why?
|
Myocarditis | 1 | 2007 | 802 | 0.160 |
Why?
|
Recovery of Function | 6 | 2020 | 2966 | 0.160 |
Why?
|
Reference Values | 3 | 2015 | 4908 | 0.160 |
Why?
|
Angina Pectoris | 2 | 2014 | 956 | 0.160 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2014 | 881 | 0.150 |
Why?
|
Coronary Occlusion | 1 | 2021 | 283 | 0.150 |
Why?
|
Nitrites | 1 | 2018 | 156 | 0.150 |
Why?
|
Longitudinal Studies | 10 | 2021 | 14751 | 0.150 |
Why?
|
Ultrasonic Therapy | 1 | 2020 | 216 | 0.150 |
Why?
|
Myocardial Infarction | 4 | 2018 | 11499 | 0.150 |
Why?
|
Walking | 2 | 2023 | 1198 | 0.150 |
Why?
|
Sternotomy | 1 | 2019 | 134 | 0.150 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2019 | 198 | 0.150 |
Why?
|
Risk Factors | 17 | 2024 | 74840 | 0.150 |
Why?
|
Pyrimidines | 2 | 2020 | 3047 | 0.150 |
Why?
|
Galectin 3 | 1 | 2019 | 238 | 0.140 |
Why?
|
Linear Models | 3 | 2020 | 5876 | 0.140 |
Why?
|
Adenoviridae | 1 | 2002 | 1092 | 0.140 |
Why?
|
Chagas Disease | 1 | 2019 | 163 | 0.140 |
Why?
|
Pyrrolidines | 1 | 2019 | 337 | 0.140 |
Why?
|
Extracellular Matrix Proteins | 1 | 2021 | 833 | 0.140 |
Why?
|
Quinoxalines | 1 | 2019 | 296 | 0.140 |
Why?
|
Trypanosoma cruzi | 1 | 2019 | 200 | 0.140 |
Why?
|
Triglycerides | 3 | 2016 | 2441 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 429 | 0.140 |
Why?
|
Young Adult | 19 | 2022 | 59889 | 0.140 |
Why?
|
Sarcomeres | 1 | 2019 | 379 | 0.140 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6309 | 0.140 |
Why?
|
Calcium-Binding Proteins | 1 | 2021 | 1077 | 0.140 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20124 | 0.140 |
Why?
|
Glucosides | 1 | 2021 | 531 | 0.140 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1480 | 0.130 |
Why?
|
Diet, Mediterranean | 1 | 2023 | 746 | 0.130 |
Why?
|
Polymyxins | 1 | 2016 | 17 | 0.130 |
Why?
|
Creatinine | 2 | 2019 | 1915 | 0.130 |
Why?
|
Diastole | 2 | 2016 | 785 | 0.130 |
Why?
|
Donor Selection | 1 | 2018 | 242 | 0.130 |
Why?
|
Fibrinolytic Agents | 1 | 2006 | 2080 | 0.130 |
Why?
|
Blood Volume | 1 | 2017 | 542 | 0.130 |
Why?
|
Trimethoprim | 1 | 2016 | 79 | 0.130 |
Why?
|
Graft Survival | 3 | 2023 | 3890 | 0.130 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2006 | 32 | 0.130 |
Why?
|
Amino Acids, Aromatic | 2 | 2012 | 36 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2022 | 1316 | 0.130 |
Why?
|
Nitrates | 1 | 2017 | 260 | 0.130 |
Why?
|
Carbon Dioxide | 2 | 2011 | 1137 | 0.130 |
Why?
|
Mucopolysaccharidosis IV | 1 | 2015 | 7 | 0.130 |
Why?
|
Hepacivirus | 2 | 2020 | 1343 | 0.120 |
Why?
|
Chondroitinsulfatases | 1 | 2015 | 16 | 0.120 |
Why?
|
Immunomodulation | 1 | 2019 | 547 | 0.120 |
Why?
|
RNA, Transfer | 1 | 2017 | 283 | 0.120 |
Why?
|
Competitive Behavior | 1 | 2015 | 77 | 0.120 |
Why?
|
Atrial Function, Left | 2 | 2015 | 189 | 0.120 |
Why?
|
Coronary Artery Disease | 4 | 2021 | 6544 | 0.120 |
Why?
|
Enzyme Replacement Therapy | 1 | 2015 | 80 | 0.120 |
Why?
|
Echocardiography, Doppler | 5 | 2017 | 899 | 0.120 |
Why?
|
Glucose Tolerance Test | 4 | 2014 | 1180 | 0.120 |
Why?
|
Naval Medicine | 1 | 2014 | 30 | 0.120 |
Why?
|
Case-Control Studies | 7 | 2018 | 22223 | 0.120 |
Why?
|
Coronary Vessels | 1 | 2006 | 3096 | 0.120 |
Why?
|
Cerebrum | 1 | 2016 | 131 | 0.120 |
Why?
|
Ancillary Services, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
Blood Glucose | 4 | 2024 | 6424 | 0.110 |
Why?
|
Tetrazoles | 1 | 2020 | 920 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 5 | 2016 | 6499 | 0.110 |
Why?
|
Liver Cirrhosis | 1 | 2025 | 1959 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.110 |
Why?
|
Massachusetts | 3 | 2020 | 8875 | 0.110 |
Why?
|
Aminoisobutyric Acids | 1 | 2014 | 39 | 0.110 |
Why?
|
Aortic Diseases | 1 | 2020 | 729 | 0.110 |
Why?
|
Endothelin-1 | 1 | 2015 | 295 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2019 | 864 | 0.110 |
Why?
|
Ventricular Pressure | 2 | 2012 | 210 | 0.110 |
Why?
|
Cardiac Myosins | 2 | 2024 | 128 | 0.110 |
Why?
|
Bariatric Surgery | 1 | 2024 | 997 | 0.110 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2015 | 122 | 0.110 |
Why?
|
Animals | 20 | 2022 | 168764 | 0.110 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2018 | 1094 | 0.110 |
Why?
|
Chronic Disease | 4 | 2022 | 9347 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2024 | 12240 | 0.110 |
Why?
|
Pilot Projects | 5 | 2023 | 8733 | 0.110 |
Why?
|
Amino Acids, Branched-Chain | 2 | 2012 | 266 | 0.100 |
Why?
|
Endothelium, Vascular | 2 | 2015 | 4427 | 0.100 |
Why?
|
Adaptation, Physiological | 5 | 2017 | 1308 | 0.100 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1377 | 0.100 |
Why?
|
Obesity, Morbid | 1 | 2024 | 1292 | 0.100 |
Why?
|
Heart Valve Prosthesis | 1 | 2021 | 1466 | 0.100 |
Why?
|
Coronary Sinus | 2 | 2014 | 85 | 0.100 |
Why?
|
Carbolines | 1 | 2014 | 288 | 0.100 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6069 | 0.100 |
Why?
|
Hypertension | 4 | 2022 | 8626 | 0.100 |
Why?
|
Aorta | 1 | 2020 | 2028 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1884 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1946 | 0.100 |
Why?
|
Laparoscopy | 1 | 2024 | 2039 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 10383 | 0.100 |
Why?
|
Bile Acids and Salts | 1 | 2014 | 398 | 0.100 |
Why?
|
Sports Medicine | 1 | 2014 | 239 | 0.100 |
Why?
|
Eicosanoids | 2 | 2023 | 284 | 0.100 |
Why?
|
Device Removal | 1 | 2017 | 646 | 0.090 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2012 | 153 | 0.090 |
Why?
|
Sex Factors | 5 | 2020 | 10603 | 0.090 |
Why?
|
Adiponectin | 3 | 2023 | 1119 | 0.090 |
Why?
|
Natriuretic Peptides | 1 | 2012 | 153 | 0.090 |
Why?
|
Propensity Score | 1 | 2019 | 1968 | 0.090 |
Why?
|
Peptide Mapping | 1 | 2011 | 259 | 0.090 |
Why?
|
Adolescent | 16 | 2021 | 88835 | 0.090 |
Why?
|
Football | 1 | 2016 | 504 | 0.090 |
Why?
|
Capillaries | 1 | 2014 | 755 | 0.090 |
Why?
|
Adipose Tissue, White | 1 | 2014 | 370 | 0.090 |
Why?
|
Brain Death | 2 | 2024 | 360 | 0.090 |
Why?
|
Antihypertensive Agents | 2 | 2020 | 2033 | 0.090 |
Why?
|
Prosthesis-Related Infections | 1 | 2016 | 496 | 0.090 |
Why?
|
Sodium Chloride | 1 | 2012 | 576 | 0.090 |
Why?
|
Heart Atria | 1 | 2016 | 1363 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1441 | 0.090 |
Why?
|
Blood Gas Analysis | 1 | 2011 | 380 | 0.090 |
Why?
|
Hepatitis C | 1 | 2020 | 1597 | 0.090 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2010 | 66 | 0.090 |
Why?
|
Mass Spectrometry | 3 | 2014 | 2194 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2024 | 10729 | 0.080 |
Why?
|
Diffusion Tensor Imaging | 1 | 2020 | 2410 | 0.080 |
Why?
|
Hypothyroidism | 1 | 2015 | 667 | 0.080 |
Why?
|
Shock, Cardiogenic | 1 | 2015 | 704 | 0.080 |
Why?
|
Lipids | 3 | 2024 | 3315 | 0.080 |
Why?
|
Apoptosis | 2 | 2016 | 9514 | 0.080 |
Why?
|
Tandem Mass Spectrometry | 3 | 2011 | 1192 | 0.080 |
Why?
|
Diuretics | 1 | 2012 | 613 | 0.080 |
Why?
|
Blood Chemical Analysis | 1 | 2011 | 433 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2016 | 2352 | 0.080 |
Why?
|
Leptin | 3 | 2023 | 1596 | 0.080 |
Why?
|
Body Composition | 1 | 2019 | 2439 | 0.080 |
Why?
|
Chromatography, Liquid | 2 | 2010 | 990 | 0.080 |
Why?
|
Uremia | 1 | 2010 | 202 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 3432 | 0.080 |
Why?
|
Isotopes | 1 | 2008 | 124 | 0.080 |
Why?
|
Interleukin-6 | 4 | 2023 | 3222 | 0.080 |
Why?
|
Severity of Illness Index | 6 | 2016 | 15880 | 0.080 |
Why?
|
Administration, Inhalation | 2 | 2018 | 1154 | 0.080 |
Why?
|
Kidney | 2 | 2024 | 7066 | 0.080 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5891 | 0.070 |
Why?
|
Sports | 1 | 2014 | 698 | 0.070 |
Why?
|
Age Factors | 5 | 2018 | 18380 | 0.070 |
Why?
|
Biological Assay | 1 | 2011 | 627 | 0.070 |
Why?
|
Aged, 80 and over | 7 | 2019 | 59489 | 0.070 |
Why?
|
Fatty Acids | 1 | 2016 | 1806 | 0.070 |
Why?
|
Registries | 3 | 2024 | 8297 | 0.070 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 737 | 0.070 |
Why?
|
Adipose Tissue, Brown | 1 | 2014 | 776 | 0.070 |
Why?
|
Vasodilation | 2 | 2015 | 970 | 0.070 |
Why?
|
Diabetic Angiopathies | 1 | 2012 | 805 | 0.070 |
Why?
|
Comorbidity | 3 | 2017 | 10563 | 0.070 |
Why?
|
Heart Defects, Congenital | 2 | 2014 | 4697 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2014 | 687 | 0.070 |
Why?
|
Kinetics | 3 | 2010 | 6274 | 0.070 |
Why?
|
Swine | 3 | 2022 | 5988 | 0.070 |
Why?
|
Incidence | 5 | 2024 | 21480 | 0.070 |
Why?
|
Dogs | 2 | 2015 | 3822 | 0.070 |
Why?
|
Logistic Models | 3 | 2020 | 13266 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2178 | 0.070 |
Why?
|
Troponin T | 1 | 2011 | 785 | 0.060 |
Why?
|
Graft Rejection | 1 | 2019 | 4499 | 0.060 |
Why?
|
Weight Loss | 2 | 2024 | 2710 | 0.060 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 192 | 0.060 |
Why?
|
Aging | 3 | 2021 | 8731 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12056 | 0.060 |
Why?
|
Sex Characteristics | 4 | 2020 | 2643 | 0.060 |
Why?
|
Inflammation | 3 | 2023 | 10850 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2012 | 937 | 0.060 |
Why?
|
Data Mining | 1 | 2010 | 562 | 0.060 |
Why?
|
Mice | 8 | 2021 | 81819 | 0.060 |
Why?
|
Reference Standards | 1 | 2008 | 1013 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4270 | 0.060 |
Why?
|
Transplantation, Heterologous | 3 | 2022 | 2394 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 1 | 2014 | 2247 | 0.060 |
Why?
|
Periodicity | 1 | 2006 | 345 | 0.060 |
Why?
|
Mortality | 1 | 2016 | 2904 | 0.060 |
Why?
|
Glucose Intolerance | 1 | 2008 | 580 | 0.060 |
Why?
|
Valsalva Maneuver | 1 | 2024 | 99 | 0.060 |
Why?
|
Microcirculation | 1 | 2009 | 1280 | 0.060 |
Why?
|
Propionates | 1 | 2024 | 180 | 0.060 |
Why?
|
Survival Rate | 4 | 2019 | 12795 | 0.050 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2004 | 204 | 0.050 |
Why?
|
Pandemics | 2 | 2020 | 8703 | 0.050 |
Why?
|
Naphthalenes | 1 | 2024 | 197 | 0.050 |
Why?
|
Uric Acid | 2 | 2024 | 809 | 0.050 |
Why?
|
Hospitalization | 5 | 2024 | 10808 | 0.050 |
Why?
|
Cyclic GMP | 1 | 2004 | 394 | 0.050 |
Why?
|
Kidney Failure, Chronic | 2 | 2020 | 2495 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2652 | 0.050 |
Why?
|
Telemedicine | 1 | 2021 | 3105 | 0.050 |
Why?
|
Epoxy Compounds | 1 | 2023 | 136 | 0.050 |
Why?
|
United States | 9 | 2023 | 72903 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2020 | 951 | 0.050 |
Why?
|
Resistin | 1 | 2023 | 174 | 0.050 |
Why?
|
Platelet Aggregation | 1 | 2006 | 769 | 0.050 |
Why?
|
Linoleic Acid | 1 | 2023 | 157 | 0.050 |
Why?
|
Prediabetic State | 1 | 2008 | 548 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2008 | 2910 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2024 | 281 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3423 | 0.050 |
Why?
|
Sewage | 1 | 2002 | 44 | 0.050 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2024 | 262 | 0.050 |
Why?
|
Psychomotor Performance | 1 | 2010 | 1881 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8501 | 0.050 |
Why?
|
Pulse | 1 | 2021 | 215 | 0.050 |
Why?
|
Signal Transduction | 2 | 2021 | 23601 | 0.050 |
Why?
|
Insulin | 3 | 2014 | 6599 | 0.050 |
Why?
|
Proteome | 1 | 2011 | 1899 | 0.050 |
Why?
|
Water Microbiology | 1 | 2002 | 116 | 0.050 |
Why?
|
Atrial Fibrillation | 2 | 2024 | 5189 | 0.040 |
Why?
|
Patient Care Team | 1 | 2012 | 2517 | 0.040 |
Why?
|
Ultrasonography | 4 | 2016 | 5993 | 0.040 |
Why?
|
Bronchodilator Agents | 1 | 2004 | 514 | 0.040 |
Why?
|
Lipolysis | 2 | 2014 | 211 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 70 | 0.040 |
Why?
|
Research Design | 1 | 2016 | 6209 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2006 | 1167 | 0.040 |
Why?
|
Plasma Volume | 1 | 2019 | 31 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2020 | 368 | 0.040 |
Why?
|
Chest Pain | 1 | 2007 | 1100 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2006 | 1602 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2006 | 1166 | 0.040 |
Why?
|
Independent Living | 1 | 2024 | 585 | 0.040 |
Why?
|
Guanylate Cyclase | 1 | 2020 | 205 | 0.040 |
Why?
|
Elasticity Imaging Techniques | 1 | 2025 | 398 | 0.040 |
Why?
|
Postoperative Complications | 2 | 2020 | 15747 | 0.040 |
Why?
|
Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
Death | 1 | 2023 | 686 | 0.040 |
Why?
|
Gastrectomy | 1 | 2024 | 694 | 0.040 |
Why?
|
Electrocardiography | 2 | 2014 | 6404 | 0.040 |
Why?
|
Parasitemia | 1 | 2019 | 164 | 0.040 |
Why?
|
Heparin | 1 | 2006 | 1630 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36532 | 0.040 |
Why?
|
Nucleotides | 2 | 2012 | 451 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2021 | 3850 | 0.040 |
Why?
|
Early Diagnosis | 2 | 2014 | 1187 | 0.040 |
Why?
|
Dilatation, Pathologic | 1 | 2020 | 527 | 0.040 |
Why?
|
Fatty Liver | 1 | 2025 | 807 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12976 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2019 | 124 | 0.040 |
Why?
|
Tachycardia, Ventricular | 1 | 2007 | 1310 | 0.040 |
Why?
|
Glucose | 1 | 2010 | 4335 | 0.040 |
Why?
|
Antibodies, Protozoan | 1 | 2019 | 250 | 0.040 |
Why?
|
Liver | 1 | 2014 | 7562 | 0.040 |
Why?
|
Computational Biology | 1 | 2010 | 3559 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 14652 | 0.040 |
Why?
|
Israel | 1 | 2020 | 725 | 0.040 |
Why?
|
Adipokines | 1 | 2020 | 308 | 0.040 |
Why?
|
Ambulatory Care | 2 | 2023 | 2778 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2024 | 1123 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7478 | 0.040 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2019 | 684 | 0.040 |
Why?
|
Neprilysin | 1 | 2020 | 484 | 0.040 |
Why?
|
Motor Activity | 1 | 2007 | 2704 | 0.040 |
Why?
|
Viremia | 1 | 2020 | 727 | 0.040 |
Why?
|
Denmark | 1 | 2019 | 774 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1659 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 538 | 0.030 |
Why?
|
Rats | 2 | 2015 | 23707 | 0.030 |
Why?
|
Motion | 1 | 2020 | 781 | 0.030 |
Why?
|
Amino Acids | 2 | 2014 | 1709 | 0.030 |
Why?
|
Heart Arrest | 1 | 2007 | 1516 | 0.030 |
Why?
|
Galectins | 1 | 2019 | 294 | 0.030 |
Why?
|
Cell Line | 1 | 2010 | 15543 | 0.030 |
Why?
|
Bicycling | 1 | 2017 | 176 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4850 | 0.030 |
Why?
|
Keratan Sulfate | 1 | 2015 | 17 | 0.030 |
Why?
|
Odds Ratio | 1 | 2008 | 9649 | 0.030 |
Why?
|
Brazil | 1 | 2019 | 1248 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 26318 | 0.030 |
Why?
|
Mutation | 1 | 2019 | 30198 | 0.030 |
Why?
|
NF-kappa B | 1 | 2003 | 2485 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 22332 | 0.030 |
Why?
|
Weight Gain | 2 | 2016 | 2355 | 0.030 |
Why?
|
Ceramides | 1 | 2016 | 201 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4562 | 0.030 |
Why?
|
Exanthema | 1 | 2019 | 502 | 0.030 |
Why?
|
Ships | 1 | 2014 | 53 | 0.030 |
Why?
|
Disease Progression | 3 | 2019 | 13632 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2015 | 317 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2002 | 1652 | 0.030 |
Why?
|
Aspirin | 1 | 2006 | 3134 | 0.030 |
Why?
|
Blood Proteins | 1 | 2019 | 1188 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2119 | 0.030 |
Why?
|
Hypotension | 1 | 2020 | 885 | 0.030 |
Why?
|
Dyslipidemias | 2 | 2012 | 869 | 0.030 |
Why?
|
Drug Resistance | 1 | 2020 | 1591 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 704 | 0.030 |
Why?
|
Atherosclerosis | 1 | 2010 | 3424 | 0.030 |
Why?
|
Tryptophan Hydroxylase | 1 | 2014 | 93 | 0.030 |
Why?
|
Gene Deletion | 1 | 2021 | 2666 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10070 | 0.030 |
Why?
|
Hyperemia | 1 | 2015 | 224 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9443 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2017 | 647 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2024 | 3715 | 0.030 |
Why?
|
Advisory Committees | 1 | 2017 | 796 | 0.030 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2019 | 845 | 0.030 |
Why?
|
Adipocytes, White | 1 | 2014 | 92 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2014 | 245 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2008 | 18973 | 0.030 |
Why?
|
Adipocytes, Brown | 1 | 2014 | 160 | 0.030 |
Why?
|
Pyridines | 1 | 2024 | 2888 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 586 | 0.030 |
Why?
|
PPAR alpha | 1 | 2014 | 175 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2018 | 2108 | 0.020 |
Why?
|
Carbohydrates | 1 | 2014 | 386 | 0.020 |
Why?
|
Procollagen | 1 | 2012 | 189 | 0.020 |
Why?
|
Fever | 1 | 2019 | 1603 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2002 | 2593 | 0.020 |
Why?
|
Organ Size | 1 | 2016 | 2260 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1326 | 0.020 |
Why?
|
Thyroid Hormones | 1 | 2014 | 410 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2601 | 0.020 |
Why?
|
Cystatin C | 1 | 2012 | 272 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2003 | 2567 | 0.020 |
Why?
|
Muscle Strength | 1 | 2015 | 637 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2020 | 2415 | 0.020 |
Why?
|
Biogenic Amines | 1 | 2010 | 53 | 0.020 |
Why?
|
GABA Plasma Membrane Transport Proteins | 1 | 2010 | 30 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2003 | 11083 | 0.020 |
Why?
|
Renin | 1 | 2012 | 647 | 0.020 |
Why?
|
Mitral Valve Stenosis | 1 | 2012 | 343 | 0.020 |
Why?
|
Physical Conditioning, Animal | 1 | 2014 | 366 | 0.020 |
Why?
|
Patient Selection | 1 | 2022 | 4255 | 0.020 |
Why?
|
Amino Acid Transport Systems | 1 | 2010 | 34 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5526 | 0.020 |
Why?
|
Glucose Metabolism Disorders | 1 | 2010 | 52 | 0.020 |
Why?
|
Dicarboxylic Acids | 1 | 2010 | 75 | 0.020 |
Why?
|
Sphingomyelins | 1 | 2010 | 102 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 607 | 0.020 |
Why?
|
Fibrosis | 1 | 2016 | 2070 | 0.020 |
Why?
|
Systems Integration | 1 | 2011 | 427 | 0.020 |
Why?
|
Intracellular Space | 1 | 2010 | 198 | 0.020 |
Why?
|
Glutamine | 1 | 2012 | 576 | 0.020 |
Why?
|
Organ Specificity | 1 | 2014 | 1965 | 0.020 |
Why?
|
Reoperation | 1 | 2019 | 4294 | 0.020 |
Why?
|
Health Behavior | 1 | 2020 | 2650 | 0.020 |
Why?
|
Fontan Procedure | 1 | 2014 | 805 | 0.020 |
Why?
|
Waist Circumference | 1 | 2012 | 932 | 0.020 |
Why?
|
Sleep | 1 | 2024 | 4813 | 0.020 |
Why?
|
Extracellular Space | 1 | 2010 | 563 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 2218 | 0.020 |
Why?
|
Dietary Proteins | 1 | 2012 | 959 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6763 | 0.020 |
Why?
|
Ketones | 1 | 2008 | 183 | 0.020 |
Why?
|
Standard of Care | 1 | 2011 | 567 | 0.020 |
Why?
|
Insulin-Secreting Cells | 1 | 2014 | 898 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15842 | 0.020 |
Why?
|
Molecular Structure | 1 | 2011 | 1885 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3685 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 874 | 0.020 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 1568 | 0.020 |
Why?
|
Phenols | 1 | 2010 | 522 | 0.020 |
Why?
|
Outpatients | 1 | 2014 | 1595 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2003 | 6364 | 0.020 |
Why?
|
Parents | 1 | 2020 | 3592 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2012 | 1789 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2015 | 6493 | 0.020 |
Why?
|
Peptide Hydrolases | 1 | 2008 | 608 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3956 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2002 | 9249 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 2003 | 6113 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3835 | 0.020 |
Why?
|
Causality | 1 | 2011 | 1248 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2016 | 2084 | 0.010 |
Why?
|
Glycolysis | 1 | 2008 | 838 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 8102 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9550 | 0.010 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2003 | 295 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2010 | 2721 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8067 | 0.010 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.010 |
Why?
|
Fasting | 1 | 2008 | 1606 | 0.010 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2014 | 1883 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2003 | 1546 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6832 | 0.010 |
Why?
|
Neuregulin-1 | 1 | 2002 | 140 | 0.010 |
Why?
|
Chick Embryo | 1 | 2003 | 964 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9338 | 0.010 |
Why?
|
Receptor, erbB-3 | 1 | 2002 | 141 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2012 | 3141 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6547 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 2393 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1799 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7425 | 0.010 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2003 | 636 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9591 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2014 | 7599 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2003 | 1336 | 0.010 |
Why?
|
Child | 2 | 2019 | 80564 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2002 | 2014 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 30260 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18071 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 9081 | 0.010 |
Why?
|
Homeostasis | 1 | 2008 | 3336 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2010 | 4913 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3807 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2014 | 11641 | 0.010 |
Why?
|
Blotting, Western | 1 | 2003 | 5020 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11888 | 0.010 |
Why?
|
Ligands | 1 | 2002 | 3273 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2002 | 21056 | 0.010 |
Why?
|
Androgens | 1 | 2002 | 1279 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4475 | 0.010 |
Why?
|
Diet | 1 | 2012 | 8086 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12131 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20659 | 0.010 |
Why?
|
Protein Binding | 1 | 2002 | 9296 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2002 | 12768 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2002 | 8611 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 13648 | 0.000 |
Why?
|